Metropolis Healthcare Limited — Investor Meet, 11-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Metropolis Healthcare reported robust Q3 FY26 results, with group revenue growing 26% YoY and organic revenue up 15%. Organic EBITDA increased 29.3%, reaching a 25% margin. The company approved a 3:1 bonus share issue.

Management is strategically focusing on high-growth specialty diagnostics, including launching its Centre of Genomics in Delhi. Operational updates include successful integration of Core Diagnostics, with improved Q4 margins expected, and network expansion into Tier 2/3 cities via franchises. The company aims for 7-8% sustained patient volume growth. The outlook remains confident for 12-13% organic growth and expanded margins for FY26, driven by efficiencies and a strong focus on complex diagnostics and preventive health.